All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

FDA 'Concerned' after Germany Reports More Heparin-Related Illnesses

March 13, 2008
By Pharmaceutical Technology Editors
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Concerns over contaminated heparin product worsened as US officials announced dialysis patients in Germany have fallen ill after using a different brand of the blood thinner than was already being recalled.

Rockville, MD (Mar. 6)-Concerns over contaminated heparin product worsened as US officials announced dialysis patients in Germany have fallen ill after using a different brand of the blood thinner than was already being recalled.

Just one week after Baxter International announced it would voluntary recall all of its remaining lots and doses of heparin sodium injection multidose, single-dose vials, and HEP-LOK heparin flush products, which were linked to 19 deaths in the United States, FDA confirmed that Germany is recalling heparin made by RotexMedica GmbH, a German company that uses a different supplier of raw heparin ingredients than Baxter does. Baxter receives its heparin material from China, the world’s largest heparin supplier. It is unknown whether RotexMedica also received its supply from China.

The incidents appear to be caused by a contaminant that mimics heparin so well that it is not detected by standard drug-quality tests. In response, FDA is urgently pushing for companies to start using advanced analytical techniques to ensure drug products are free of this contaminant and has posted instructions on its website on how manufacturers can do these additional tests to identify the fake ingredient.

“We’re concerned about, worldwide, this contaminant in heparin and making sure it stays out of the heparin supply,” said Janet Woodcock, FDA chief medical officer, to the Associated Press.

Reports have stated that German officials have not confirmed that the heparin product by RotexMedica has been recalled. Meanwhile, as reported in the February 28 edition of ePT, APP Pharmaceuticals has boosted its manufacture in efforts to keep up with market demand.

For more on this topic, see:

Active Ingredient in Baxter's Recalled Heparin Made in China, Feb. 21 edition of ePT

Baxter Voluntarily Recalls Heparin Lots, Feb. 14 edition of ePT

Recent Videos
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

3d rendering of Human cell or Embryonic stem cell microscope background. | Image Credit: © Anusorn - stock.adobe.com

Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck

John Tomtishen
May 28th 2025
Article

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


An antiviral used to treat hepatitis B and C | Image Credit © luchschenF

pharma& Secures MHRA Approval for Pegasys API Production at Loba Biotech

Christopher Cole
May 28th 2025
Article

MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Sanofi logo at one of skyscraper. Sanofi is a French biopharma company | Image Credit: © Robert - stock.adobe.com

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Christopher Cole
May 23rd 2025
Article

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.


Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.

Related Content

3d rendering of Human cell or Embryonic stem cell microscope background. | Image Credit: © Anusorn - stock.adobe.com

Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck

John Tomtishen
May 28th 2025
Article

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


An antiviral used to treat hepatitis B and C | Image Credit © luchschenF

pharma& Secures MHRA Approval for Pegasys API Production at Loba Biotech

Christopher Cole
May 28th 2025
Article

MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Sanofi logo at one of skyscraper. Sanofi is a French biopharma company | Image Credit: © Robert - stock.adobe.com

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Christopher Cole
May 23rd 2025
Article

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.


Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.